This final conversation focus on what Sober Livers leaders Jenn Jones and Beth Lehman hope listeners will take from this discussion and ways they can help HOPE.
In this conversation, Society for Sober Livers leaders Jenn Jones and Beth Lehman discuss their plans for the future of HOPE.
Roger Green asks Sober Livers leaders Jenn Jones and Beth Lehman questions about services and future plans for HOPE, their unique support program for patients who have harmed themselves through ALD.
In this conversation, Roger Green asks why ALD patients who have harmed themselves through drinking will benefit from a unique support organization like HOPE.
Sober Livers Founder/Visionary Jenn Jones and Principal Strategic Advisor Beth Lehman join Roger Green to discuss HOPE, a unique, multi-element support program for people who have harmed their bodies through ALD.
Roger Green is joined by Sober Livers Founder/Visionary Jenn Jones and Principal Strategic Advisor Beth Lehman to discuss HOPE, (Healing Others with Peers and Education), a support program launching June 11 for people who have harmed their bodies through ALD and its consequences.
As the conversation wraps up, Jörn Schattenberg and Michelle Long discusses abstracts they will present at EASL Congress 2024, with Jörn focusing on new MASLD drug development and Michelle on an aggregation of studies sponsored by Novo Nordisk.
Two abstracts for the EASL Congress 2024 from Hannes Hagstrom’s team leads the group to focus on the future of Big Data within MASLD diagnosis and therapies.
This conversation starts when co-host Jörn Schattenberg joins our EASL Congress 20224 preview. The episode itself focuses on the future of hepatology along with other MASLD abstracts and presentations.
This conversation centers around two thoughts about the EASL Congress 2024 from Michelle Long.one on network value and the other on the reat benefit that comes from reviewing abstracts in advance.
